SCHEMBL4272844

SCHEMBL4272844

CC(C)N(C)CCc1ccc(N)cc1Cl

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 3/20 0.40
AOC3 Q16853 1/20 0.40
CYP3A4 P08684 3/20 0.39
TAAR1 Q96RJ0 1/20 0.39
TSHR P16473 2/20 0.38
HTR2C P28335 2/20 0.36
HTR2B P41595 1/20 0.36
ACHE P22303 1/20 0.36
EPHX2 P34913 1/20 0.35
NR1H4 Q96RI1 1/20 0.35
CA1 P00915 1/20 0.35
CA2 P00918 1/20 0.35
ALDH1A1 P00352 1/20 0.35
THRB P10828 1/20 0.35
HPGD P15428 1/20 0.35
ALOX15 P16050 1/20 0.35
CASP1 P29466 1/20 0.35
RECQL P46063 1/20 0.35
HSD17B10 Q99714 1/20 0.35
SLC6A4 P31645 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3868321 0.77 CHRM2 (0.50) HTR2AAOC3CYP3A4TAAR1TSHR
SCHEMBL5779838 0.76 CHIA (0.50) HTR2AAOC3CYP3A4TAAR1TSHR
SCHEMBL3787093 0.73 CYP3A4 (0.48) CYP3A4TAAR1TSHRHTR2CACHE
SCHEMBL6676181 0.73 TAAR1 (0.56) CYP3A4TAAR1TSHREPHX2NR1H4
SCHEMBL1299722 0.73 CYP3A4 (0.52) CYP3A4TAAR1TSHREPHX2NR1H4
SCHEMBL23882976 0.72 KDM4E (0.40) HTR2AAOC3CYP3A4TAAR1TSHR
SCHEMBL30001237 0.72 KDM4E (0.40) HTR2AAOC3CYP3A4TAAR1TSHR
SCHEMBL3197622 0.72 SLC6A4 (0.54) HTR2ACYP3A4TSHREPHX2NR1H4
SCHEMBL20869634 0.71 SIGMAR1 (0.34) HTR2ACYP3A4HTR2CHTR2BACHE
SCHEMBL4009082 0.71 KCNH2 (0.48) CYP3A4TSHRHTR2CACHESLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7605176-B2 β-ketoamide compounds with MCH antagonistic activity BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-10-20 US disclosed
EP-1730130-A1 BETA-KETOAMIDE COMPOUNDS HAVING AN MCH-ANTAGONISTIC EFFECT AND MEDICAMENTS CONTAINING SAID COMPOUNDS Boehringer Ingelheim International GmbH (DE) 2006-12-13 EP disclosed
US-20050245500-A1 Beta-ketoamide compounds with MCH antagonistic activity BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2005-11-03 US disclosed
WO-2005085221-A1 BETA-KETOAMIDE COMPOUNDS HAVING AN MCH-ANTAGONISTIC EFFECT AND MEDICAMENTS CONTAINING SAID COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2005-09-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050245500-A1 Beta-ketoamide compounds with MCH antagonistic activity MCHR2, MCHR1, NPY1R HTR2A 225/4885AOC3 3372/4885CYP3A4 3281/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.